Ivan Chivite
Overview
Explore the profile of Ivan Chivite including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laguno M, de Lazzari E, Berrocal L, Inciarte A, Martinez-Rebollar M, de la Mora L, et al.
HIV Med
. 2024 Nov;
25(12):1308-1324.
PMID: 39508213
Background: Liver steatosis (LS) and liver fibrosis (LF) can increase the risk of cardiovascular disease in people with HIV, but their prevalence and associated factors are poorly understood. This study...
2.
de Lazzari E, Nomah D, Blanco J, Rico N, Filella X, Egri N, et al.
Int J Infect Dis
. 2024 Oct;
149:107266.
PMID: 39423949
Objectives: The prevalence and risk factors of SARS-CoV-2 infection among unvaccinated people living with HIV (PWH) are not well understood, and the protective role of tenofovir remains controversial. This study...
3.
Palacio-Vieira J, Diaz Y, Moreno-Fornes S, Bruguera A, Nomah D, Llibre J, et al.
Int J STD AIDS
. 2024 Aug;
35(12):952-962.
PMID: 39148144
Background: People lost to follow-up (LTFU) from HIV care have an increased risk of worse health. The objective of this study is to create and validate a risk score to...
4.
Ugarte A, de la Mora L, de Lazzari E, Chivite I, Fernandez E, Inciarte A, et al.
J Antimicrob Chemother
. 2024 Jul;
79(9):2343-2353.
PMID: 39045754
Introduction: Rapid initiation of ART after HIV diagnosis is recommended for individual and public health benefits. However, certain clinical and ART-related considerations hinder immediate initiation of therapy. Methods: An open-label,...
5.
Chivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, et al.
J Antimicrob Chemother
. 2024 May;
79(8):1775-1783.
PMID: 38758191
Background: The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is based on the results of robust clinical trials. Objectives: To assess the effectiveness and safety of BIC/FTC/TAF in treatment-naïve (TN) and treatment-experienced...
6.
Inciarte A, de la Mora L, Huaier-Arriazu E, Torres B, Canizares S, Zamora E, et al.
Infect Dis Ther
. 2024 Apr;
13(4):647-658.
PMID: 38570445
Background: A broadened clinical spectrum of concomitant complications emerges among the escalating incidence of substance use, particularly within the 'chemsex' context. This case exemplifies the profound neurotoxic repercussions and neurological...
7.
Vaz-Pinto I, Ortega E, Chivite I, Buti M, Turnes-Vazquez J, Magno-Pereira V, et al.
Front Public Health
. 2024 Feb;
11:1268888.
PMID: 38328544
Background: Around 57,000 people in Spain and Portugal currently living with HIV or chronic hepatitis C are unaware of their infection. The COVID-19 pandemic severely disrupted screening efforts for these...
8.
Borjabad B, Inciarte A, Chivite I, Gonzalez-Cordon A, Mosquera M, Hurtado C, et al.
J Antimicrob Chemother
. 2023 Dec;
79(2):255-261.
PMID: 38039097
Background: Decreasing medication burden with raltegravir plus lamivudine in virologically suppressed persons with HIV (PWH) maintained efficacy and was well tolerated at 24 weeks, but more comprehensive data over longer...
9.
Rocabert A, Borjabad B, Berrocal L, Blanch J, Inciarte A, Chivite I, et al.
J Antimicrob Chemother
. 2023 Oct;
78(12):2961-2967.
PMID: 37875023
Background: While both the burden of therapy and the individual drugs in bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) and dolutegravir/lamivudine differ, it is unclear whether their real-life tolerability may be also different. Methods:...
10.
Inciarte A, Ugarte A, Martinez-Rebollar M, Torres B, Fernandez E, Berrocal L, et al.
Open Forum Infect Dis
. 2023 Aug;
10(8):ofad374.
PMID: 37539061
Background: New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For this reason, we evaluated the single-tablet regimen of doravirine/lamivudine/tenofovir disoproxil...